CatalystMarker
Sign in
← board

MEDP

distress 1/10 · well-funded / low risk
$616.02+17%today-1% from 52w high
medpace.com6,300 employeesFounded 1992Cincinnati, OHDiagnostics & Research
Revenue
$707M
Liquidity
$653M
Runway
Shares 1y
+1%

Price & events

+1.6% over 6M
$393$505$616Jan 26Apr 26Jul 261.6Mcatalyst: earnings (2026-07-22) — click to openrating: Mizuho: Outperform (2026-07-13)rating: Baird: Outperform → Neutral (2026-07-08)rating: Jefferies: Buy → Hold (2026-07-07)rating: RBC Capital: Outperform (2026-04-24)rating: BMO Capital: Market Perform (2026-04-24)rating: Baird: Outperform (2026-04-24)rating: Barclays: Equal-Weight (2026-04-24)rating: Barclays: Underweight → Equal-Weight (2026-03-06)
CatalystRating changeDilutionFinancingdashed = today
+16.6%
1D
+14.5%
1W
+30.1%
1M
+56.6%
3M
+4.8%
6M
+40.8%
1Y
+72.4%
2Y
+238.2%
5Y
+358.3%
All

Overview

Market Cap
$17.59B
Volume
263.40K
52 Week Range
$309 – $621
Total Shares
28.56M
Float Shares
22.47M
Short %
9.23%
% Held by Insiders
19.43%
% Held by Institutions
87.17%
RVOL
0.82x

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 2

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 28,559,689 · 0 offerings/1y · 0 PIPEs
  • 2025-07-218-Kmaterial_agreement
  • 2025-04-218-Kmaterial_agreement
  • 2025-03-318-Kmaterial_agreement
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

hold · target $472 (-23% upside) · 12 analysts
  • 2026-07-13MizuhoOutperform
  • 2026-07-08BairdOutperform → Neutral
  • 2026-07-07JefferiesBuy → Hold
  • 2026-04-24RBC CapitalOutperform
  • 2026-04-24BMO CapitalMarket Perform
  • 2026-04-24BairdOutperform

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.